PPARG and urinary bladder carcinoma: We further confirmed this dependence using PPARγ-specific antagonist T0070907 in human bladder cancer lines HT-1197 carrying the endogenous RXRαS427F, and 5637 and UM-UC941 lines bearing PPARγ amplifications (Fig. 3e, Supplementary Fig. 12).